Latest News
Study identifies likely cause of childhood leukaemia
23 May 2018 - Acute lymphoblastic leukaemia (ALL) is the most common type of childhood cancer, affecting one in 2,000 children. It is particularly prevalent in advanced, affluent societies and figures show it is increasing globally at a rate of aroun...
Cara Therapeutics agrees worldwide licensing deal for KORSUVA injection
23 May 2018 - Cara Therapeutics Inc (Nasdaq: CARA) has entered into a licensing agreement for KORSUVA (CR845/difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in dialysis patients, the US biopharmaceuti...
Atlanta Center for Medical Research names Eric Riesenberg as CEO
23 May 2018 - Clinical research company Atlanta Center for Medical Research (ACMR) revealed on Tuesday the appointment of Eric Riesenberg (CPA) as its chief executive officer.Effective immediately, Riesenberg succeeds his father and the company'...
WuXi Biologics Partners with Bioasis to Develop and Manufacture Investigational Brain Cancer Treatment
23 May 2018 - - Wuxi, China-based biologics technology platform company WuXi Biologics (2269.HK) and Vancouver, British Columbia-based biopharmaceutical company Bioasis Technologies, Inc. (TSX.V: BTI) (OTCQB: BIOAF) have formed a strategic collaborat...
Precigen Commences Phase 1 Clinical Study of Triple-effector Plasmid in LVAD Patients
23 May 2018 - - Germantown, Maryland-based biopharmaceutical company Precigen, Inc., a wholly-owned subsidiary of synthetic biology company Intrexon Corp. (NYSE: XON), has treated the first patient in a Phase 1 first-in-human clinical trial of its in...